SOPHSOPHiA Genetics SA

SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to...

U.S. stock futures trading higher. CarMax, Sophia Genetics, Jabil, La-Z-Boy, and Safe Bulkers in focus. La-Z-Boy shares jump 17.7% after earnings.read more...

SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares PR Newswire BOSTON and ROLLE, Switzerland, June 16, 2026 BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA...

SOPHiA GENETICS Announces Proposed Public Offering of Ordinary Shares SOPHiA GENETICS Announces Proposed Public Offering of Ordinary Shares PR Newswire BOSTON and ROLLE, Switzerland, June 16, 2026 BOSTONand ROLLE,Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global...

SOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General Meeting SOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General Meeting PR Newswire BOSTON and ROLLE, Switzerland, June 10, 2026 Ross Muken to assume the role of Chief Executive Officer effective July 1...

SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center PR Newswire NEW YORK, June 4, 2026 SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center Aim to Establish Precision Medicine...

Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K. Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the...

BTIG Research restated a "buy" rating and set a $8.00 target price on shares of SOPHiA GENETICS in a report on Wednesday...

SOPHiA GENETICS (NASDAQ:SOPH) reported first-quarter 2026 revenue of $21.7 million, up 22% from $17.8 million in the prior-year period, as demand increased for its SOPHiA DDM analytics platform and the company expanded its installed base of clinical customers and applications. Revenue growth and re...